Technische Universität Dresden, Faculty of Medicine Carl Gustav Carus, Department of General Practice/MK3, Dresden, Germany; Municipal Hospital Bielefeld, Department for Endocrinology and Diabetes, Bielefeld, Germany; GesundheitsZentrum Kelkheim.
Dtsch Arztebl Int. 2017 Jun 23;114(25):430-438. doi: 10.3238/arztebl.2017.430.
The prevalence of latent/subclinical hypothyroidism is between 3% and 10%, according to epidemiologic studies that have been carried out in the USA, the United Kingdom, and Denmark. As persons with latent hypo - thyroidism are often asymptomatic, the diagnosis is often made incidentally in routine laboratory testing.
This review is based on a selective search in PubMed for publications on the diagnosis and treatment of latent hypothyroidism. All pertinent articles and guidelines published from 1 January 2000 to 31 July 2016 were included.
The diagnosis of latent hypothyroidism is generally assigned after repeated measurement of a TSH concentration above 4.0 mU/L in a person whose fT4 concentration is in the normal range. The most common cause is autoimmune thyroiditis, which can be detected by a test for autoantibodies. L-thyroxin supplementation is a controversial matter: its purpose is to prevent the development of overt hypothyroidism, but there is a danger of overtreatment, which increases the risk of fracture. To date, no benefit of L-thyroxin supplementation has been demonstrated with respect to morbidity and mortality, health-related quality of life, mental health, cognitive function, or reduction of overweight. There is, however, evidence of a beneficial effect on cardiac function in women, and on the vascular system. At present, treatment is generally considered indicated only if the TSH level exceeds 10.0 mU/L.
Limited data are available on the relevant clinical endpoints and undesired side effects of supplementation therapy. Physicians should advise patients about the indications for such treatment on an individual basis after due consideration of the risks and benefits.
根据在美国、英国和丹麦进行的流行病学研究,亚临床/潜伏性甲状腺功能减退症的患病率在 3%至 10%之间。由于潜伏性甲状腺功能减退症患者通常无症状,因此通常是在常规实验室检测中偶然发现的。
本综述基于对 PubMed 中有关潜伏性甲状腺功能减退症诊断和治疗的出版物的选择性搜索。纳入了 2000 年 1 月 1 日至 2016 年 7 月 31 日期间发表的所有相关文章和指南。
一般在重复测量 TSH 浓度>4.0 mU/L 后,诊断为潜伏性甲状腺功能减退症,且患者的 fT4 浓度在正常范围内。最常见的原因是自身免疫性甲状腺炎,可以通过自身抗体检测来发现。L-甲状腺素替代治疗存在争议:其目的是预防显性甲状腺功能减退症的发生,但存在过度治疗的风险,增加骨折的风险。迄今为止,L-甲状腺素替代治疗在发病率和死亡率、健康相关生活质量、心理健康、认知功能或超重减轻方面的获益尚未得到证实。然而,有证据表明,它对女性的心脏功能和血管系统有益。目前,一般认为仅当 TSH 水平超过 10.0 mU/L 时才需要进行治疗。
关于补充治疗的相关临床终点和不良副作用的数据有限。医生应在充分考虑风险和获益的基础上,根据患者的具体情况,就此类治疗的适应证向患者提供建议。